In vivo response to electrochemically aligned collagen bioscaffolds
In vivo response to electrochemically aligned collagen bioscaffolds
复制标题
DOI：
10.1002/jbm.b.31962
复制
发表时间：
2012-02-01
影响因子：
3.4
通讯作者：
Akkus, Ozan
中科院分区：
文献类型：
--
作者：
Kishore, Vipuil;Uquillas, Jorge Alfredo;Akkus, Ozan
基于胶原蛋白的生物材料是肌腱重建和修复的可行选择。然而，胶原蛋白结构的机械强度较弱是一个主要限制。我们之前报道过一种新的方法来形成高度定向的电化学排列胶原蛋白（ELAC）线，其机械性能与天然肌腱的机械性能一致。在这项研究中，我们评估了兔髌腱 (PT) 对编织 ELAC 生物支架的体内反应。将兔 PT 纵向切开，并将 ELAC 生物支架沿肌腱长度镶嵌在一侧肢体中。对侧肢体作为假手术对照。术后4或8个月对兔子实施安乐死。高分辨率射线照片显示生物支架周围不存在异位骨形成。植入后四个月，组织学切片显示 ELAC 生物支架经历了有限的降解，并与低度肉芽肿性炎症相关。此外，定量组织学显示，具有 ELAC 生物支架的 PT 的横截面积比对照组大 29%。此外，与对照组相比，经过 ELAC 处理的 PT 明显更硬。与对照组相比，经 ELAC 处理的 PT 肌腱束的体积分数有所增加。 8个月时，ELAC生物支架大部分被吸收，植入物肌腱区域的扩大随着肉芽肿性炎症的消退而消退。我们得出的结论是，ELAC 具有生物相容性和可生物降解性，有潜力用作肌腱组织工程应用的生物材料。 (C) 2011 Wiley periodicals, Inc. J Biomed Mater Res B 部分：Appl Biomater 100B：400408，2012。
Collagen-based biomaterials are a viable option for tendon reconstruction and repair. However, the weak mechanical strength of collagen constructs is a major limitation. We have previously reported a novel methodology to form highly oriented electrochemically aligned collagen (ELAC) threads with mechanical properties converging on those of the natural tendon. In this study, we assessed the in vivo response of rabbit patellar tendon (PT) to braided ELAC bioscaffolds. Rabbit PTs were incised longitudinally and the ELAC bioscaffold was inlaid in one limb along the length of the tendon. The contralateral limb served as the sham-operated control. Rabbits were euthanized at 4 or 8 months postoperatively. High-resolution radiographs revealed the absence of ectopic bone formation around the bioscaffolds. Four months post-implantation, the histological sections showed that the ELAC bioscaffold underwent limited degradation and was associated with a low-grade granulomatous inflammation. Additionally, quantitative histology revealed that the cross-sectional areas of PTs with the ELAC bioscaffold were 29% larger compared with the controls. Furthermore, ELAC-treated PTs were significantly stiffer compared with the controls. The volume fraction of the tendon fascicle increased in the ELAC-treated PT compared with the controls. By 8 months, the ELAC bioscaffold was mostly absorbed and the enlargement in the area of tendons with implants subsided along with the resolution of the granulomatous inflammation. We conclude that ELAC is biocompatible and biodegradable and has the potential to be used as a biomaterial for tendon tissue engineering applications. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 100B: 400408, 2012.